vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and C3.ai, Inc. (AI). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $75.1M, roughly 1.9× C3.ai, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -139.3%, a 174.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -20.3%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-46.9M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -2.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
C3.ai, Inc. is a leading enterprise artificial intelligence software provider that develops and delivers scalable AI applications, platform tools, and industry-specific solutions for clients across sectors including manufacturing, energy, financial services, healthcare and public sector. Its offerings help organizations optimize operations, reduce costs, mitigate risks, and realize data-driven decision making.
ADMA vs AI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $75.1M |
| Net Profit | $49.4M | $-104.7M |
| Gross Margin | 63.8% | 40.4% |
| Operating Margin | 45.1% | -149.2% |
| Net Margin | 35.5% | -139.3% |
| Revenue YoY | 18.4% | -20.3% |
| Net Profit YoY | -55.9% | -58.7% |
| EPS (diluted) | $0.20 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $75.1M | ||
| Q3 25 | $134.2M | $70.3M | ||
| Q2 25 | $122.0M | $108.7M | ||
| Q1 25 | $114.8M | $98.8M | ||
| Q4 24 | $117.5M | $94.3M | ||
| Q3 24 | $119.8M | $87.2M | ||
| Q2 24 | $107.2M | $86.6M | ||
| Q1 24 | $81.9M | $78.4M |
| Q4 25 | $49.4M | $-104.7M | ||
| Q3 25 | $36.4M | $-116.8M | ||
| Q2 25 | $34.2M | $-79.7M | ||
| Q1 25 | $26.9M | $-80.2M | ||
| Q4 24 | $111.9M | $-66.0M | ||
| Q3 24 | $35.9M | $-62.8M | ||
| Q2 24 | $32.1M | $-72.9M | ||
| Q1 24 | $17.8M | $-72.6M |
| Q4 25 | 63.8% | 40.4% | ||
| Q3 25 | 56.3% | 37.6% | ||
| Q2 25 | 55.1% | 62.1% | ||
| Q1 25 | 53.2% | 59.1% | ||
| Q4 24 | 53.9% | 61.3% | ||
| Q3 24 | 49.8% | 59.8% | ||
| Q2 24 | 53.6% | 59.6% | ||
| Q1 24 | 47.8% | 57.8% |
| Q4 25 | 45.1% | -149.2% | ||
| Q3 25 | 38.0% | -177.7% | ||
| Q2 25 | 35.1% | -81.8% | ||
| Q1 25 | 30.4% | -88.7% | ||
| Q4 24 | 32.6% | -79.8% | ||
| Q3 24 | 33.1% | -83.2% | ||
| Q2 24 | 36.6% | -95.1% | ||
| Q1 24 | 26.7% | -105.3% |
| Q4 25 | 35.5% | -139.3% | ||
| Q3 25 | 27.1% | -166.2% | ||
| Q2 25 | 28.1% | -73.3% | ||
| Q1 25 | 23.4% | -81.2% | ||
| Q4 24 | 95.2% | -69.9% | ||
| Q3 24 | 30.0% | -72.0% | ||
| Q2 24 | 29.9% | -84.2% | ||
| Q1 24 | 21.7% | -92.6% |
| Q4 25 | $0.20 | $-0.75 | ||
| Q3 25 | $0.15 | $-0.86 | ||
| Q2 25 | $0.14 | $-0.60 | ||
| Q1 25 | $0.11 | $-0.62 | ||
| Q4 24 | $0.45 | $-0.52 | ||
| Q3 24 | $0.15 | $-0.50 | ||
| Q2 24 | $0.13 | $-0.59 | ||
| Q1 24 | $0.08 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $675.0M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $771.9M |
| Total Assets | $624.2M | $961.3M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $675.0M | ||
| Q3 25 | $61.4M | $711.9M | ||
| Q2 25 | $90.3M | $742.7M | ||
| Q1 25 | $71.6M | $724.3M | ||
| Q4 24 | $103.1M | $730.4M | ||
| Q3 24 | $86.7M | $762.5M | ||
| Q2 24 | $88.2M | $750.4M | ||
| Q1 24 | $45.3M | $723.3M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $771.9M | ||
| Q3 25 | $431.2M | $798.8M | ||
| Q2 25 | $398.3M | $838.3M | ||
| Q1 25 | $373.4M | $860.2M | ||
| Q4 24 | $349.0M | $859.0M | ||
| Q3 24 | $231.9M | $874.9M | ||
| Q2 24 | $188.3M | $873.4M | ||
| Q1 24 | $153.7M | $898.0M |
| Q4 25 | $624.2M | $961.3M | ||
| Q3 25 | $568.7M | $968.7M | ||
| Q2 25 | $558.4M | $1.0B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.0B | ||
| Q3 24 | $390.6M | $1.1B | ||
| Q2 24 | $376.4M | $1.0B | ||
| Q1 24 | $350.9M | $1.1B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-46.5M |
| Free Cash FlowOCF − Capex | $34.6M | $-46.9M |
| FCF MarginFCF / Revenue | 24.8% | -62.4% |
| Capex IntensityCapex / Revenue | 0.8% | 0.5% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-93.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-46.5M | ||
| Q3 25 | $13.3M | $-33.5M | ||
| Q2 25 | $21.1M | $11.3M | ||
| Q1 25 | $-19.7M | $-22.0M | ||
| Q4 24 | $50.2M | $-38.7M | ||
| Q3 24 | $25.0M | $8.0M | ||
| Q2 24 | $45.6M | $21.3M | ||
| Q1 24 | $-2.2M | $-39.1M |
| Q4 25 | $34.6M | $-46.9M | ||
| Q3 25 | $-1.1M | $-34.3M | ||
| Q2 25 | $18.7M | $10.3M | ||
| Q1 25 | $-24.4M | $-22.4M | ||
| Q4 24 | $47.5M | $-39.5M | ||
| Q3 24 | $24.0M | $7.1M | ||
| Q2 24 | $43.6M | $18.8M | ||
| Q1 24 | $-4.6M | $-45.1M |
| Q4 25 | 24.8% | -62.4% | ||
| Q3 25 | -0.8% | -48.8% | ||
| Q2 25 | 15.3% | 9.5% | ||
| Q1 25 | -21.2% | -22.7% | ||
| Q4 24 | 40.4% | -41.9% | ||
| Q3 24 | 20.0% | 8.2% | ||
| Q2 24 | 40.7% | 21.7% | ||
| Q1 24 | -5.6% | -57.6% |
| Q4 25 | 0.8% | 0.5% | ||
| Q3 25 | 10.7% | 1.1% | ||
| Q2 25 | 2.0% | 0.9% | ||
| Q1 25 | 4.1% | 0.4% | ||
| Q4 24 | 2.3% | 0.9% | ||
| Q3 24 | 0.9% | 1.1% | ||
| Q2 24 | 1.9% | 2.9% | ||
| Q1 24 | 2.9% | 7.8% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AI
| License And Service | $70.2M | 93% |
| Professional Services | $4.9M | 7% |
